The role of entacapone in the management of Parkinson's disease.
Catechol-O-methyltransferase (COMT) inhibition is an important advance in the treatment of Parkinson's disease. This consensus statement provides guidelines for the optimal use of the only currently available COMT inhibitor, entacapone (Comtess, Orion Pharma (UK) Ltd, Newbury, Berkshire).
Brooks
D J
DJ
Imperial College School of Medicine, Hammersmith Hospital, London.
Forsyth
D
D
Playfer
J R
JR
Williams
A C
AC
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D008297:Male; D009570:Nitriles; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D004791:Enzyme Inhibitors; D009570:Nitriles; D010919:Placebos; D007980:Levodopa; C071192:entacapone